Date published: 2026-8-12

1-800-457-3801

SCBT Portrait Logo
Seach Input

apoC-IV CRISPR/Cas9 KO Plasmid (m): sc-418944

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • apoC-IV CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the apoC-IV genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    apoC-IV CRISPR/Cas9 KO Plasmid (m)

    sc-418944
    20 µg
    $397.00

    Overview

    Apoc4 encodes apolipoprotein C-IV (apoC-IV), a secreted apolipoprotein primarily associated with circulating lipoprotein particles and involved in lipid transport and remodeling. In mouse, apoC-IV is linked to regulation of triglyceride-rich lipoprotein metabolism and interfaces with pathways controlling lipoprotein lipase activity, hepatic lipid handling, and lipid exchange among VLDL/IDL/HDL fractions. Variation in apolipoprotein composition can influence systemic energy balance and inflammatory signaling indirectly through altered lipid flux and lipid-derived mediators. As such, Apoc4 is relevant to studies of dyslipidemia mechanisms, cardiometabolic phenotypes, and liver-centric lipid homeostasis in physiological and disease-model contexts.

    apoC-IV CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Apoc4 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Apoc4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Apoc4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish apoC-IV protein expression.

    This CRISPR knockout system enables efficient generation of Apoc4-deficient cell models for investigation of apoC-IV signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Apoc4 exon(s) critical for apoC-IV function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Apoc4 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by apoC-IV CRISPR/Cas9 KO Plasmid (m) and apoC-IV CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Apoc4 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by apoC-IV HDR Plasmid (m) and apoC-IV HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Apoc4 homology arms to support homology-directed repair at defined Apoc4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.